SCHEMBL10273897

SCHEMBL10273897

CCCc1cccc(S(=O)(=O)NC)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 2/20 0.51
HTR6 P50406 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
METAP2 P50579 1/20 0.46
TNNI3K Q59H18 4/20 0.44
EGFR P00533 1/20 0.44
ALDH1A1 P00352 1/20 0.44
GAA P10253 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
CYP19A1 P11511 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12217548 0.86 KAT6A (0.49) KAT6AHTR6L3MBTL1METAP2TNNI3K
SCHEMBL28049651 0.85 CYP4F2 (0.47) HTR6L3MBTL1TNNI3KEGFRALDH1A1
SCHEMBL12630230 0.82 ALDH1A1 (0.51) HTR6L3MBTL1ALDH1A1POLB
SCHEMBL27876496 0.82 HTR6 (0.61) KAT6AHTR6METAP2ALDH1A1GAA
SCHEMBL10213284 0.81 LMNA (0.45) HTR6L3MBTL1TNNI3KEGFRALDH1A1
SCHEMBL8277423 0.81 KEAP1 (0.65) KAT6AL3MBTL1ALDH1A1SMN1; SMN2LMNA
SCHEMBL3060871 0.81 L3MBTL1 (0.47) HTR6L3MBTL1TNNI3KEGFRALDH1A1
SCHEMBL5293352 0.81 IKBKB (0.48) L3MBTL1TNNI3KEGFRALDH1A1GAA
SCHEMBL1014348 0.81 HTR6 (0.55) HTR6L3MBTL1TNNI3KEGFRGAA
SCHEMBL22070843 0.81 L3MBTL1 (0.47) HTR6L3MBTL1TNNI3KEGFRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088758-A1 FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS F12, F11, F5 KAT6A 2581/4885HTR6 3071/4885L3MBTL1 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.